Merck

Merck Serono announces final efficiency program for Switzerland

Wednesday, June 20, 2012 10:03 AM

After a long consultation process, Merck Serono, the biopharmaceutical division of Merck, had made its final plan for restructuring its operations in Switzerland, closing its Geneva and Coinsins sites.

More... »

Ambrx, Merck collaborate to develop biologic drug conjugates

Monday, June 18, 2012 03:21 PM

Ambrx, a La Jolla, Calif.-based clinical-stage biopharmaceutical company, has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site-specific protein medicinal chemistry technology.

More... »

Dr. Reddy's and Merck Serono collaborate on biosimilars

Wednesday, June 6, 2012 01:07 PM

Dr. Reddy's Laboratories, an integrated global pharmaceutical company, and Merck Serono, a division of Merck, have formed a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs).

More... »

Codexis extends collaboration with Merck to 2015

Wednesday, May 23, 2012 09:50 AM

Redwood City, Calif.-based Codexis, a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals and pharmaceuticals, has extended its catalyst and process development collaboration with Merck to develop enzymes for use in pharmaceutical manufacturing for three more years.

More... »

Merck announces Swiss efficiency program, closure of Geneva office

Wednesday, April 25, 2012 10:05 AM

Global pharmaceutical and chemical company Merck Serono has announced efficiency plans for its Swiss operations as part of its comprehensive transformation program—focused on addressing unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization.

More... »

Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

Merck, Endocyte to develop and commercialize cancer drug vintafolide

Monday, April 16, 2012 10:55 AM

Merck has entered into an agreement with Endocyte, a biopharmaceutical company based in West Lafayette, Ind., to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145), which gained orphan drug status from the E.U. in March.

More... »

Flagship and Merck to foster early-stage life sciences innovation

Wednesday, April 11, 2012 12:37 PM

Flagship Ventures, a venture capital firm focused on healthcare and sustainability, has partnered with Merck Research Laboratories (MRL) and its newly formed Merck Research Ventures Fund to back new ventures that apply scientific breakthroughs to the development of new drugs in areas of unmet medical need.

More... »

Threshold earns $20 million milestone payment from Merck

Wednesday, April 11, 2012 11:50 AM

Threshold Pharmaceuticals, a biotech based in South San Francisco, has earned a $20 million milestone payment from Merck for achieving a statistically significant progression free survival benefit in its 214-patient randomized controlled phase II clinical trial (404 trial).

More... »

Burrill wraps up life sciences industry for Q1 2012

Wednesday, April 4, 2012 03:00 PM

Burrill & Company, a diversified global financial services firm focused on the life sciences industry, has identified more than $2.6 billion in expected funding through nine translational research and early-stage initiatives announced since the end of February.

More... »